OpenAI launches GPT-Rosalind for life sciences and drug discovery
OpenAI launched GPT-Rosalind in research preview for qualified customers including Amgen, Moderna, the Allen Institute, and Thermo Fisher through ChatGPT, Codex, and the API.
From the sources (12 posts)
@businessOpenAI Takes on Google With New AI Model Aimed at Drug Discovery
@wallstengine$NVO $TMO $MRNA $RXRX $DNA Axios: OpenAI launched GPT-Rosalind, a new life sciences model aimed at drug discovery and research. The company says it is being rolled out in research preview to qualified customers including Amgen, Moderna, Al
@stockmktnewzOpenAI is rolling out an early version of GPT-Rosalind an AI model meant to speed up drug discoveries OpenAI said some of the people using the model include with Moderna $MRNA and Amgen $AMGN - Bloomberg
@andrewcurran_New model: GPT‑Rosalind. For biology research, drug discovery, and translational medicine.
@andrewcurran_Quoting from the announcement: 'GPT‑Rosalind is now available as a research preview in ChatGPT, Codex, and the API for qualified customers through our trusted access program. We’re also introducing a freely accessible Life Sciences research
@openaiIntroducing GPT-Rosalind, our frontier reasoning model built to support research across biology, drug discovery, and translational medicine.
@openaiOn average, it takes roughly 10 to 15 years to go from target discovery to regulatory approval for a new drug in the United States. Advanced AI systems can help researchers move faster — not just by making existing work more efficient, but
@openaiGPT-Rosalind, our Life Sciences model series, is optimized for scientific workflows, with stronger performance in protein and chemical reasoning, genomics analysis, biochemistry knowledge, and scientific tool use.
@openaiOur Life Sciences model series is available as a research preview starting today for qualified customers including @Amgen, @moderna_tx, the @AllenInstitute, and @thermofisher Scientific through ChatGPT, Codex, and the API.
@andrewcurran_This is a new series: 'This is the first release in our GPT‑Rosalind life sciences model series, and we will continue to expand the frontiers of the model’s biochemical reasoning capabilities across long-horizon, tool-heavy scientific workf
@andrewcurran_Special guest: Lieutenant Colonel Kevin Weil.
@kimmonismusOpenAI released GPT-Rosalind today, a frontier reasoning model purpose-built for life sciences research, available in trusted-access preview to customers like Amgen, Moderna, and the Allen Institute. On the benchmarks, it's competent rath